Third Harmonic Bio, Inc. (THRD)
Automate Your Wheel Strategy on THRD
With Tiblio's Option Bot, you can configure your own wheel strategy including THRD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol THRD
- Rev/Share 0.0
- Book/Share 6.0694
- PB 0.9029
- Debt/Equity 0.011
- CurrentRatio 54.0958
- ROIC -0.2405
- MktCap 247300322.0
- FreeCF/Share -0.9283
- PFCF -5.9309
- PE -4.6054
- Debt/Assets 0.0107
- DivYield 0
- ROE -0.1927
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | THRD | Stifel | Buy | Hold | $23 | $5 | March 28, 2025 |
| Downgrade | THRD | Morgan Stanley | Overweight | Equal Weight | $20 | $5 | Feb. 12, 2025 |
| Downgrade | THRD | Raymond James | Outperform | Market Perform | -- | -- | Feb. 11, 2025 |
News
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Third Harmonic Bio, Inc. (THRD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
Published: February 12, 2025 by: Benzinga
Sentiment: Negative
On Tuesday, Third Harmonic Bio, Inc. THRD revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers.
Read More
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced results …
Read More
About Third Harmonic Bio, Inc. (THRD)
- IPO Date 2022-09-14
- Website https://www.thirdharmonicbio.com
- Industry Biotechnology
- CEO Ms. Natalie C. Holles
- Employees 31